Lisata Therapeutics (NASDAQ:LSTA) Stock Price Down 3.1%

Lisata Therapeutics, Inc. (NASDAQ:LSTA – Get Rating)’s share price fell 3.1% during mid-day trading on Tuesday . The company traded as low as $3.22 and last traded at $3.32. 3,505 shares were traded during trading, a decline of 74% from the average session volume of 13,492 shares. The stock had previously closed at $3.43.

Lisata Therapeutics Stock Down 3.1 %

The company has a market capitalization of $26.10 million, a PE ratio of -0.27 and a beta of 1.17. The company’s 50-day moving average price is $3.41.

Institutional Investors Weigh In On Lisata Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP purchased a new position in shares of Lisata Therapeutics in the third quarter worth about $57,000. State Street Corp acquired a new position in Lisata Therapeutics in the third quarter valued at approximately $66,000. BlackRock Inc. purchased a new stake in Lisata Therapeutics in the third quarter valued at approximately $263,000. Renaissance Technologies LLC acquired a new position in shares of Lisata Therapeutics in the third quarter valued at approximately $467,000. Finally, BML Capital Management LLC purchased a new stake in shares of Lisata Therapeutics in the fourth quarter valued at approximately $617,000. 6.00% of the stock is owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

(Get Rating)

Lisata Therapeutics, Inc develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively.